Show simple item record

dc.contributor.authorZhong, Huanzi
dc.contributor.authorRen, Huahui
dc.contributor.authorLu, Yan
dc.contributor.authorFang, Chao
dc.contributor.authorHou, Guixue
dc.contributor.authorYang, Ziyi
dc.contributor.authorChen, Bing
dc.contributor.authorYang, Fangming
dc.contributor.authorZhao, Yue
dc.contributor.authorShi, Zhun
dc.contributor.authorZhou, Baojin
dc.contributor.authorWu, Jiegen
dc.contributor.authorZou, Hua
dc.contributor.authorZi, Jin
dc.contributor.authorChen, Jiayu
dc.contributor.authorBao, Xiao
dc.contributor.authorHu, Yihe
dc.contributor.authorGao, Yan
dc.contributor.authorZhang, Jun
dc.contributor.authorXu, Xun
dc.contributor.authorHou, Yong
dc.contributor.authorYang, Huanming
dc.contributor.authorWang, Jian
dc.contributor.authorLiu, Siqi
dc.contributor.authorJia, Huijue
dc.contributor.authorMadsen, Lise
dc.contributor.authorBrix, Susanne
dc.contributor.authorKristiansen, Karsten
dc.contributor.authorLiu, Fang
dc.contributor.authorLi, Junhua
dc.date.accessioned2020-04-02T08:38:59Z
dc.date.available2020-04-02T08:38:59Z
dc.date.created2020-03-28T14:09:43Z
dc.date.issued2019
dc.identifier.citationEBioMedicine. 2019, 47 373-383.en_US
dc.identifier.issn2352-3964
dc.identifier.urihttps://hdl.handle.net/11250/2650021
dc.description.abstractBackground The gut microbiota plays important roles in modulating host metabolism. Previous studies have demonstrated differences in the gut microbiome of T2D and prediabetic individuals compared to healthy individuals, with distinct disease-related microbial profiles being reported in groups of different age and ethnicity. However, confounding factors such as anti-diabetic medication hamper identification of the gut microbial changes in disease development. Method We used a combination of in-depth metagenomics and metaproteomics analyses of faecal samples from treatment-naïve type 2 diabetic (TN-T2D, n = 77), pre-diabetic (Pre-DM, n = 80), and normal glucose tolerant (NGT, n = 97) individuals to investigate compositional and functional changes of the gut microbiota and the faecal content of microbial and host proteins in Pre-DM and treatment-naïve T2D individuals to elucidate possible host-microbial interplays characterizing different disease stages. Findings We observed distinct differences characterizing the gut microbiota of these three groups and validated several key features in an independent TN-T2D cohort. We also demonstrated that the content of several human antimicrobial peptides and pancreatic enzymes differed in faecal samples between three groups. Interpretation Our findings suggest a complex, disease stage-dependent interplay between the gut microbiota and the host and point to the value of metaproteomics to gain further insight into interplays between the gut microbiota and the host.en_US
dc.language.isoengen_US
dc.titleDistinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-naive type 2 diabeticsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber373-383en_US
dc.source.volume47en_US
dc.source.journalEBioMedicineen_US
dc.identifier.doi10.1016/j.ebiom.2019.08.048
dc.identifier.cristin1804081
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record